General Aspects and Mechanisms of Peripheral Neuropathy Associated With Bortezomib in Patients With Newly Diagnosed Multiple Myeloma

Seminars in Hematology

Volumn 49, Issue 3, 2012, Pages 249-257

  Broyl, Annemiek ^a   Jongen, Joost L M ^a   Sonneveld, Pieter ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BORTEZOMIB; CARBAMAZEPINE; CARFILZOMIB; DEXAMETHASONE; DOXORUBICIN; GABAPENTIN; GLUTAMINE; LENALIDOMIDE; LEVACECARNINE; LIDOCAINE; MELPHALAN; NARCOTIC ANALGESIC AGENT; NORADRENALIN UPTAKE INHIBITOR; PREDNISONE; PREGABALIN; PYRIDOXINE; SALINOSPORAMIDE A; SEROTONIN UPTAKE INHIBITOR; THALIDOMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; VINCRISTINE; VITAMIN B GROUP;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL FEATURE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; HIGH RISK POPULATION; HUMAN; MOTOR DYSFUNCTION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEURALGIA; NEUROLOGIC EXAMINATION; NEUROPATHIC PAIN; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; RISK FACTOR; SENSORY NEUROPATHY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; HUMANS; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES; QUALITY OF LIFE;

EID: 84862673001     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.04.001     Document Type: Article

References (48)

1. Cata J.P., Weng H.R., Burton A.W., Villareal H., Giralt S., Dougherty P.M. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 2007, 8:296-306.
2. Tariman J.D., Love G., McCullagh E., Sandifer S. Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs 2008, 12:29-36.
3. Kelly J.J. The evaluation of peripheral neuropathy. Part I: clinical and laboratory evidence. Rev Neurol Dis 2004, 1:133-140.
4. Windebank A.J., Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008, 13:27-46.
5. Jagannath S., Barlogie B., Berenson J., et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004, 127:165-172.
6. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
7. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
8. Richardson P.G., Briemberg H., Jagannath S., et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24:3113-3120.
9. Richardson P.G., Sonneveld P., Schuster M.W., et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009, 144:895-903.
10. Harousseau J.L., Attal M., Leleu X., et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006, 91:1498-1505.
11. Sonneveld P., Schmidt-Wolf I., van der Holt B., et al. HOVON-65/GMMG-HD4 Randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). Blood 2010, 116:40.
12. Mateos M.V., Richardson P.G., Schlag R., et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010, 28:2259-2266.
13. Cavo M., Tacchetti P., Patriarca F., et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010, 376:2075-2085.
14. Dimopoulos M.A., Kastritis E., Christoulas D., et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 2010, 24:1769-1778.
15. Palumbo A., Bringhen S., Rossi D., et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010, 28:5101-5109.
16. Badros A., Goloubeva O., Dalal J.S., et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007, 110:1042-1049.
17. Borrello I., Ferguson A., Huff C.A., et al. Bortezomib and thalidomide treatment of newly diagnosed patients with multiple myeloma-efficacy and neurotoxicity. Blood 2006, 108:3528.
18. Richardson P.G., Xie W., Mitsiades C., et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009, 27:3518-3525.
19. Ropper A.H., Gorson K.C. Neuropathies associated with paraproteinemia. N Engl J Med 1998, 338:1601-1607.
20. Dimopoulos M.A., Mateos M.V., Richardson P.G., et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 2010, 86:23-31.
21. Broyl A., Corthals S.L., Jongen J.L., et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 2010, 11:1057-1065.
22. Corthals S.L., Kuiper R., Johnson D.C., et al. Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica 2011, 96:1728-1732.
23. Cavaletti G., Gilardini A., Canta A., et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007, 204:317-325.
24. 2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005, 65:3828-3836.
25. Siau C., Bennett G.J. Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy. Anesth Analg 2006, 102:1485-1490.
26. Ravaglia S., Corso A., Piccolo G., et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol 2008, 119:2507-2512.
27. Roccaro A.M., Vacca A., Ribatti D. Bortezomib in the treatment of cancer. Recent Pat Anticancer Drug Discov 2006, 1:397-403.
28. Ricci D.S., Favis R., Sun Y., et al. Pharmacogenomic (PGx) analysis of bortezomib-associated peripheral neuropathy in the phase 3 VISTA trial of bortezomib plus melphalan-prednisone versus melphalan-prednisone in multiple myeloma. Blood 2009, 114:3875.
29. Common Toxicity Criteria version 2.0 and 3.0 2006, National Cancer Institute, National Cancer Institute, Bethesda, MD.
30. Cella D.F., Tulsky D.S., Gray G., et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993, 11:570-579.
31. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
32. Ajani J.A., Welch S.R., Raber M.N., Fields W.S., Krakoff I.H. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990, 8:147-159.
33. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
34. Common Toxicity Criteria vesion 4.0 2010, National Cancer Institute, National Cancer Institute, Bethesda, MD.
35. Postma T.J., Heimans J.J., Muller M.J., Ossenkoppele G.J., Vermorken J.B., Aaronson N.K. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998, 9:739-744.
36. Cavaletti G., Frigeni B., Lanzani F., et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 2007, 12:210-215.
37. Bringhen S., Larocca A., Rossi D., et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010, 116:4745-4753.
38. Delforge M., Blade J., Dimopoulos M.A., et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010, 11:1086-1095.
39. Moreau P., Pylypenko H., Grosicki S., et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011, 12:431-440.
40. Wolf S., Barton D., Kottschade L., Grothey A., Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008, 44:1507-1515.
41. Levine S., Saltzman A. Pyridoxine (vitamin B6) neurotoxicity: enhancement by protein-deficient diet. J Appl Toxicol 2004, 24:497-500.
42. Levine S., Saltzman A. Pyridoxine (vitamin B6) toxicity: enhancement by uremia in rats. Food Chem Toxicol 2002, 40:1449-1451.
43. Catley L., Anderson K.C. Velcade and vitamin C: too much of a good thing?. Clin Cancer Res 2006, 12:3-4.
44. Perrone G., Hideshima T., Ikeda H., et al. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 2009, 23:1679-1686.
45. Colvin L.A., Johnson P.R., Mitchell R., Fleetwood-Walker S.M., Fallon M. From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol. J Clin Oncol 2008, 26:4519-4520.
46. Khan M.L., Stewart A.K. Carfilzomib: a novel second-generation proteasome inhibitor. Future Oncol 2010, 7:607-612.
47. Chauhan D., Singh A., Brahmandam M., et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008, 111:1654-1664.
48. Harousseau J.L., Attal M., Avet-Loiseau H., et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010, 28:4621-4629.